Compounding HRT Solutions for Insulin-Like Growth Factor Support Patients

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline on growth hormone deficiency, fatigue associated with low insulin-like growth factor (IGF) support may present as persistent diminished stamina, early muscle tiredness, and slow recovery after physical activity. Patients may also experience reduced capacity for sustained exercise, daytime sleepiness, and a generalized sense of heaviness. The Endocrine Society notes that cognitive slowing, poor concentration, and reduced motivation may accompany physical exhaustion, making routine tasks feel disproportionately burdensome. Patients experiencing severe or worsening fatigue should seek evaluation from a qualified clinician, as these symptoms may indicate an underlying endocrine condition requiring assessment and management.

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline on growth hormone deficiency, decreased muscle mass may occur in the context of altered insulin-like growth factor (IGF) signaling, as IGF-1 plays a role in promoting protein synthesis and muscle cell maintenance. Patients may notice reduced strength, difficulty maintaining prior levels of physical activity, and progressive loss of lean body mass. According to NIDDK, changes in body composition — including loss of muscle and increases in adipose tissue — may be associated with growth hormone-related conditions in adults. Patients experiencing significant unexplained muscle loss should seek evaluation from a qualified clinician, as this may reflect a condition requiring clinical assessment.

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline on growth hormone deficiency, poor wound healing may be associated with insufficient insulin-like growth factor (IGF) support. Wounds may close slowly, remain open or re-open, and exhibit thin or pale granulation tissue, weak scar formation, and reduced tensile strength. Patients may notice prolonged redness, persistent wound drainage, frequent minor infections, and a reduced sense of healing progression, as the normal processes of cell proliferation, collagen deposition, and angiogenesis may be blunted in this setting. Patients with wounds that do not heal as expected should seek evaluation from a qualified clinician, as persistent non-healing wounds may indicate a condition requiring clinical attention.

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline on growth hormone deficiency, increased body fat — particularly central, visceral, and abdominal adiposity — may be associated with altered insulin-like growth factor (IGF) signaling. Fat storage may increase and lipolysis may be blunted, with adipocyte size and number potentially increasing, producing changes in body composition that may include a softer midsection and difficulty reducing fat even with typical diet and activity levels. According to NIDDK, these metabolic shifts may be observed in adults with growth hormone-related conditions. Patients experiencing unexplained changes in body composition should seek evaluation from a qualified clinician, as these findings may reflect an underlying endocrine condition.

According to the FDA-approved prescribing information for Mecasermin, Mecasermin is a recombinant human insulin-like growth factor-1 (IGF-1) indicated for the long-term treatment of growth failure in pediatric patients with severe primary IGF-1 deficiency, or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. The labeling describes that Mecasermin acts through the IGF-1 receptor to stimulate cellular growth and differentiation and exerts insulin-like metabolic effects including promotion of glucose uptake. Per the labeling, Mecasermin may cause hypoglycemia, and patients are advised to eat shortly before or after dosing; other notable risks described in the labeling include intracranial hypertension, slipped capital femoral epiphysis, and progression of scoliosis. Any compounded preparation involving Mecasermin is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Mecasermin products are separately regulated, and clinical decisions regarding its use belong with the prescribing clinician.

According to the FDA-approved prescribing information for Zinc (as applicable to FDA-reviewed zinc supplement formulations) and per NIH MedlinePlus, Zinc is an essential trace element involved in numerous enzymatic and signaling processes, including those associated with growth hormone receptor activity and hepatic IGF-1 synthesis. The labeling and NIH resources describe that Zinc deficiency may impair normal growth and metabolic function, and that correction of deficiency under clinician guidance may support normal physiological pathways. Per the labeling, excessive Zinc intake may cause adverse effects including gastrointestinal symptoms and interference with copper absorption, and supplementation should occur under clinician oversight. Any compounded preparation involving Zinc is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Zinc products are separately regulated, and clinical decisions regarding their use belong with the prescribing clinician.